Protocols should be in line with OECD Guideline 471 (Salmonella typhimurium Reverse Mutation Test), 472 (Escherichia coli Reverse Mutation Test), 473 (in vitro Mammalian Chromosomal Aberration Test), 474 (Mammalian Erythrocyte Micronucleus Test), 475 (Mammalian Bone Marrow Chromosomal Aberration Test), 476 (in vitro Mammalian Cell Gene Mutation Test) or 482 (Unscheduled DNA Synthesis in Mammalian Cells in vitro), as well as other relevant OECD Guidelines for in vitro and in vivo assays.
Die Verfahren sollten einer der folgenden OECD-Leitlinien sowie sonstigen einschlägigen OEC
D-Leitlinien für In-vitro- und In-vivo-Tests entsprechen: 471 (Salmonella typhimuri
um Reverse Mutation Test), 472 (Escherichia coli Reverse Mutation T
est), 473 (In vitro Mammalian Chromosome Aberration Test), 474 (Mammalian Erythrocyte Micronucleus Test), 475 (Ma
mmalian Bone Marrow Chromosome ...[+++] Aberration Test), 476 (In vitro Mammalian Cell Gene Mutation Test) oder 482 (Genetic Toxicology: DNA Damage and Repair, Unscheduled DNA Synthesis in Mammalian Cells in vitro).